GlaxoSmithKline and Dynavax to develop TLRs

GlaxoSmithKline (GSK) and Dynavax Technologies are to collaborate on a project to develop novel inhibitors of endosomal Toll-like Receptors (TLRs).

These can induce inflammatory responses in the body as they are key receptors of the immune system.

TLRs will be developed and commercialised by the two companies to treat immune-inflammatory diseases, GSK stated.

Dynavax’s role in the partnership will be to undertake research and early clinical development, with the potential to earn approximately $200 million (129.9 million pounds) per each of the four programmes targeting conditions such as lupus, rheumatoid arthritis and psoriasis.

If GSK wishes, it can then license these and carry out more research on the projects to commercialise them.

GSK’s senior vice-president and head of the immune-inflammation centre of excellence for drug discovery Jose Carlos Gutierrez Ramos said the company was “committed” to combining its expertise with that of Dynavax to produce new therapeutics.

“Dynavax is a recognised pioneer in the scientific community for its innovation of endosomal TLR inhibitors which prevent immune signalling in autoimmune and inflammatory diseases,” he added.

Meanwhile, earlier this month GSK announced it had extended its tender offer to buy outstanding shares in Genelabs Technologies.